Can β-Caryophyllene Help Overcome Chemotherapy Resistance? What the Research Really Shows
Updated: 2 days ago
What if one of cancer’s defenses could be weakened—not by inventing a new chemotherapy drug, but by helping an existing medicine stay inside a cancer cell long enough to work?
That intriguing possibility is driving research into β-caryophyllene (BCP), a naturally occurring compound found in black pepper, cloves, and several aromatic plants. Early experiments suggest BCP can increase the accumulation of certain chemotherapy agents in cancer cells. But the science is still preclinical, and that distinction matters.
Why cancer cells can become resistant to chemotherapy
Chemotherapy needs to reach vulnerable targets inside cancer cells. Some tumors develop ways to resist its effects: repairing damage, changing survival signals, or pumping drugs back out. These pumps are called efflux transporters. Think of them as microscopic exit doors that can keep the drug concentration inside the cell too low to be effective.
One of the best-studied is P-glycoprotein, also called P-gp or ABCB1. It transports several anticancer drugs, including paclitaxel and doxorubicin. Other transporters such as MRP1, MRP2, and BCRP can also contribute to resistance, depending on the cancer and treatment.
Where β-caryophyllene enters the picture
BCP is a fat-soluble plant sesquiterpene best known in cannabinoid research for its activity at the CB2 receptor. Researchers are also examining its effects on cell membranes, drug transport and signaling pathways involved in whether cancer cells survive treatment.
There are three important possibilities: BCP might change how easily a chemotherapy drug crosses the cell membrane; it might alter the activity or expression of transport proteins such as P-gp; or it might influence cell-survival pathways, including STAT3, that shape the response to chemotherapy. These possibilities may overlap. More drug inside a cell does not, by itself, prove that BCP directly blocks an efflux pump.
What laboratory studies have found
Paclitaxel, 2007: In breast and colon cancer cell-line experiments, Legault and Pichette found that BCP enhanced paclitaxel activity. At one tested concentration, a fluorescent paclitaxel marker accumulated about 64% more inside treated cells. The researchers proposed improved movement across the membrane rather than straightforward P-gp blockade.
Doxorubicin, 2017: Researchers working with human cancer cell lines, including drug-resistant leukemia cells, reported that BCP and its related compound β-caryophyllene oxide enhanced doxorubicin’s cytotoxic effects and increased retention of rhodamine 123, a marker used to study transporter activity. The oxide generally showed stronger effects. These were cell experiments, not patient outcomes.
Liver cancer cells, 2020: In HepG2 cells, BCP increased the cellular accumulation of doxorubicin and rhodamine 123. At 50 micromolar, rhodamine accumulation rose by about 29%. Investigators also observed changes in doxorubicin-induced P-gp expression. Computer modeling suggested a potential interaction with the transporter, but modeling alone cannot establish direct inhibition.
Bile-duct cancer cells, 2020: In a cholangiocarcinoma model, BCP enhanced the action of doxorubicin under some exposure schedules and influenced STAT3 signaling, redox defenses and cell-cycle regulation. Crucially, a longer exposure schedule did not show the same benefit and instead produced evidence of antagonism. The combination, dose and timing all matter.
The important difference between promising and proven
Taken together, the findings suggest BCP may be a candidate chemotherapy sensitizer: a compound that makes some cancer cells more susceptible to an existing anticancer drug. Of the efflux transporters, ABCB1/P-gp has the most substantial BCP-related laboratory evidence. Claims about direct inhibition of BCRP, MRP7 and other pumps are much less established.
There is also a safety question. Drug-export transporters are not exclusive to cancer. They help protect healthy tissues in the intestine, liver, kidneys and blood-brain barrier. Altering their activity could increase the exposure—and potentially the toxicity—of chemotherapy drugs.
No human regimen has established that BCP reverses chemotherapy resistance, improves survival or safely permits chemotherapy dose reduction. Patients receiving cancer treatment should not add BCP supplements to intensify chemotherapy without their oncology team’s guidance.
What researchers need to answer next
The next steps include measuring actual transporter activity, testing whether the effect disappears when P-gp is removed from cells, separating membrane effects from direct pump inhibition, and studying drug levels and toxicity in living systems. Well-designed clinical trials would then be needed before any treatment claim could be justified.
The bottom line
The intriguing story is that BCP has shown measurable effects on drug accumulation and treatment sensitivity in selected laboratory models—and researchers now have specific questions to test. In cancer medicine, making a promising laboratory discovery useful for patients requires both persistence and proof.
Scientific references
Legault J, Pichette A. Journal of Pharmacy and Pharmacology (2007). https://pubmed.ncbi.nlm.nih.gov/18053325/
Di Giacomo S et al. Anticancer Research (2017). https://pubmed.ncbi.nlm.nih.gov/28314281/
Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC7014471/
Di Sotto A et al. Cells (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC7226839/
Ahmed EA. Molecules (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12029853/
Educational information only. This article does not recommend replacing, modifying or supplementing prescribed cancer treatment.
Comments